I've mostly examined cell-based vectors, ie engineered viruses that grow on cells, or a bacterial/fungal vector for the neoepitopes. The major cost savings that

I've mostly examined cell-based vectors, ie engineered viruses that grow on cells, or a bacterial/fungal vector for the neoepitopes. The major cost savings that I have seen is to shrink the size of the per-person manufacturing facility from a clean room that can hold a technician down to a box roughly the size of a microwave that uses robotics. This can shrink a 7 figure $ cost down to 5- to 6- figures.